Skip to content

Short-Term Transcutaneous or Epidural Spinal Stimulation for Enabling Motor Function in Humans With SCI

A Pilot Study to Compare Short-Term Transcutaneous or Epidural Spinal Stimulation for Enabling Motor Function in Humans With Spinal Cord Injury

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05095454
Enrollment
6
Registered
2021-10-27
Start date
2022-03-04
Completion date
2023-03-30
Last updated
2024-07-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Paralysis, Paraplegia, Quadraplegia, Tetraplegia

Brief summary

A study comparing short-term delivery of epidural spinal stimulation versus transcutaneous spinal stimulation.

Detailed description

The purpose of this study is to compare spinal motor nerve response to electrical stimulation delivered directly to the epidural space, and delivered through the skin (transcutaneously), and to measure any changes in motor performance over the course of about 5 months, during and after using one of the two types of stimulation.

Interventions

DEVICEPercutaneous epidural electrical spinal stimulation

Abbott percutaneous trial lead for epidural neurostimulation (Model 3086) Ripple Neuromed Nomad Neurostimulation System

DEVICETranscutaneous electrical spinal stimulation

Digitimer DS8R Bipolar Constant Current Stimulator

Sponsors

Kristin Zhao, PhD
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
22 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Spinal cord injury due to trauma located at or above the tenth thoracic vertebrae (T10) * American Spinal Injury Association grading scale of A-D (2 from each) below the level of SCI * Intact spinal reflexes below the level of SCI * At least 1-year post-SCI * At least 22 years of age * Willing to use medically acceptable methods of contraception, if female and of child-bearing potential

Exclusion criteria

* Currently a prison inmate, or awaiting trial, related to criminal activity * Pregnancy at the time of enrollment * History of chronic and/or treatment resistant urinary tract infection * Unhealed decubitus ulcer * Unhealed skeletal fracture * Untreated clinical diagnosis of depression * Undergoing, or planning to undergo, diathermy treatment * Active participation in another interventional clinical trial * Presence of conditions or disorders which require MRI monitoring * A history of coagulopathy or other significant cardiac or medical risk factors for surgery * Current use of a ventilator * Clinically diagnosed cardiopulmonary complications such as chronic obstructive pulmonary disease, cardiac failure, or heart arrhythmia that contraindicate changes in body position such as supine-to-sit-to-stand activities, prolonged standing, or stepping * History of frequent hypotension characterized by light headedness, or loss of consciousness * History of frequent hypertension characterized by headache, or bradycardia * History of frequent, severe, autonomic dysreflexia * Any illness or condition which, based on the research team's assessment, will compromise with the patient's ability to comply with the protocol, patient safety, or the validity of the data collected during this study.

Design outcomes

Primary

MeasureTime frameDescription
ElectromyographyThrough study completion; an average of 5 months.Change in voltage measurements in major muscle groups below the level of injury. Specifically, change in soleus root mean square voltage during standing with and without stimulation.
Foot PressureBeginning of intervention to end of intervention, an average of 17 days.Change in measurements of foot pressure in kilograms through shoe-insole pressure sensors.
Somatosensory Evoked PotentialsAssessed at Baseline, 4 Weeks, 8 Weeks, and 20 Weeks; change from Baseline at week 20 reported.Measurements of change in voltage in the conduction of electricity through the peripheral nerves, cervical and lumbosacral spinal cord, deep brain structures, and sensory cortex, using surface electrodes.
Transcranial Magnetic Stimulation Motor Evoked PotentialsAssessed at Baseline, 4 Weeks, 8 Weeks, and 20 Weeks; change from Baseline at week 20 reported.Measurement of the threshold percentage change in voltage between pre-intervention and post-intervention in the first trapezius or deltoid muscle activated.
Injury Severity: International Standards for Neurological Classification of Spinal Cord InjuryAssessed at Baseline, 4 Weeks, 8 Weeks, and 20 Weeks; change from Baseline at week 20 reported.Change sensory and motor function impairment using the American Spinal Injury Association Impairment Scale. Individuals are classified from A (complete SCI) to E (normal function). 28 dermatomes and 10 key muscles are assessed bilaterally. Summed results produce overall sensory and motor scores and combine with evaluation of anal sensory and motor function in determination of AIS classification. Sensory scores are rated 0 (sensation absent) to 2 (normal), bilaterally for each of 28 dermatomes. Muscle function is rated 0 (total paralysis) to 5 (active movement, full range of motion against significant resistance) for each myotome. Upper Extremity Motor Subscores and Lower Extremity Motor Subscores are scored from 0 to 50; the ASIA Motor Score is scored from 0 to 100. The presence of deep anal pressure and voluntary anal contraction are assessed as a yes/no; absence of these, in addition to sensory scores of 0 at S4-5 indicate a Complete injury (otherwise, the injury is Incomplete).
Patient-reported Bowel FunctionAssessed at Baseline, 4 Weeks, 8 Weeks, and 20 Weeks; change from Baseline at week 20 reported.Measurement of change in bowel function using the Neurogenic Bowel Dysfunction Score. Answers to qualitative questions are rated from 0 to 5, with a higher number indicating more problematic symptoms, and totaled for a score which categorizes severity of neurogenic bowel symptoms. The total score ranges between 0 and 44 points. A higher total score indicates more severe bowel symptoms.
Patient-reported Bladder FunctionAssessed at Baseline, 4 Weeks, 8 Weeks, and 20 Weeks; change from Baseline at week 20 reported.Measurement of change in bladder function using the Neurogenic Bladder Symptom Score. Answers to qualitative questions are rated from 0 to 5, with a higher number indicating more problematic symptoms, and totaled for a score which categorizes severity of neurogenic bladder symptoms. The total score can range from 0 (no symptoms at all) to 74 (maximum symptoms).
Male Patient-reported Sexual Function (1)Assessed at Baseline, 4 Weeks, 8 Weeks, and 20 Weeks; change from Baseline at week 20 reported.Measurement of change in erectile dysfunction using the Sexual Health Inventory for Men (SHIM). Answers to qualitative questions are rated from 0 to 5, with a higher number indicating better erectile function, and totaled for a score which categorizes severity of erectile dysfunction. Total score can range from 1 to 25, with a lower number indicating more severe erectile dysfunction.
Male Patient-reported Sexual Function (2)Assessed at Baseline, 4 Weeks, 8 Weeks, and 20 Weeks; change from Baseline at week 20 reported.Measurement of change in erectile dysfunction using the International Index for Erectile Function (IIEF). Answers to qualitative questions are rated from 0 to 5, with a higher number indicating better erectile function, and totaled for a score which categorizes severity of erectile dysfunction. Total scores range from 5 to 25, with a lower score indicating more severe erectile dysfunction.
Female Patient-reported Sexual FunctionAssessed at Baseline, 4 Weeks, 8 Weeks, and 20 Weeks; change from Baseline at week 20 reported.Measurement of change in sexual function using the Female Sexual Function Index (FSFI). Answers to qualitative questions are rated from 0 to 5, with a higher number indicating better sexual function, and totaled for a score which categorizes severity of sexual dysfunction.
SpasticityAssessed at Baseline, 4 Weeks, 8 Weeks, and 20 Weeks; change from Baseline at week 20 reported.Change in measurements of spasticity using the Spinal Cord Injury Spasticity Evaluation Tool (SCI-SET). Answers to qualitative questions are rated from -3 to +3, with a higher positive number indicating more helpful symptoms, and a lower negative number indicating more problematic symptoms. Questions may also be answered as not applicable (N/A), which do not generate a score. Scores are totaled for a score which categorizes the overall positive or negative impact of a subject's spasticity symptoms. Total score can range from -105 (negative impact) to +105 (positive impact), and the score is averaged by total positive or negative score divided by the number of applicable answers.
Neurostimulation User ExperienceEnd of intervention, an average of 4 weeksRating of the subject's perception of individual aspects of spinal stimulation using the User Experience Questionnaire (UEQ), a survey including 26 descriptive terms and their antonyms. A scoring scale ranging from 1 to 7 determines how closely the subject feels the term or its antonym applies to the intervention, with lower numbers indicating agreement with the term, and higher numbers indicating agreement with the antonym. The terms and antonyms describe a positive and negative perception of each item. Subscales grouping terms into like categories average scores into a 7 point range from -3 to +3, with negative averages associated with negative perceptions, and positive averages associated with positive perceptions.
Overground Ambulation [as Appropriate to the Subject]Baseline, 4 Weeks, 8 Weeks, and 20 WeeksMeasurement of changes in overground mobility as measured by the Modified 6 Minute Walk Test. Trainers will assess the distance in meters which the subject can cover in 6 minutes, with a greater distance characterizing better overground mobility.
Trunk StabilityBeginning of intervention to end of intervention, an average of 17 days, 8 weeks post beginning of intervention, 20 weeks post beginning of intervention; change from beginning of intervention at week 20 reported.Changes in trunk stability based on stable forward reach measured in centimeters, with a greater distance of forward reach characterizing greater trunk stability. Specifically, change in forward reach at the end of the study when comparing stimulation assisted reach and non-stimulation assisted reach.
Neurostimulator Lead Location and Migration [Epidural Group Only]Pre-intervention and 4 weeks post-interventionEvaluation of current array location via CT.
Bladder Function TestingBeginning of study, prior to initiating intervention; End of 4 weeks of intervention.Change in measurements of bladder function (end fill detrusor value) utilizing a urodynamic test consisting of a filling phase and a voiding phase cystometrogram along with perineal patch muscle electromyography.

Countries

United States

Participant flow

Recruitment details

Recruitment was conducted from March 4, 2022 to October 11, 2022 within a medical clinic.

Participants by arm

ArmCount
Percutaneous Epidural Stimulation
Epidural spinal stimulation will be delivered via percutaneously implanted electrodes during rehabilitation. All implanted electrodes will be removed at the end of trial participation. The effects of epidural stimulation will be recorded via electrophysiological and biomechanical metrics described within the outcomes measures. Percutaneous epidural electrical spinal stimulation: Abbott percutaneous trial lead for epidural neurostimulation (Model 3086) Ripple Neuromed Nomad Neurostimulation System
3
Transcutaneous Epidural Stimulation
Transcutaneous spinal stimulation will be delivered via skin surface-level electrodes during rehabilitation. The effects of transcutaneous stimulation will be recorded via electrophysiological and biomechanical metrics described within the outcomes measures. Transcutaneous electrical spinal stimulation: Digitimer DS8R Bipolar Constant Current Stimulator
3
Total6

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall StudyLengthy COVID-19 infection interrupted intervention to an unsatisfactory degree.01

Baseline characteristics

CharacteristicPercutaneous Epidural StimulationTranscutaneous Epidural StimulationTotal
Age, Customized
22-29
2 Participants2 Participants4 Participants
Age, Customized
30-39
0 Participants1 Participants1 Participants
Age, Customized
40-49
1 Participants0 Participants1 Participants
Race/Ethnicity, Customized
Black or African American
0 Participants0 Participants0 Participants
Race/Ethnicity, Customized
Hispanic or Latino
0 Participants0 Participants0 Participants
Race/Ethnicity, Customized
Multiracial
0 Participants0 Participants0 Participants
Race/Ethnicity, Customized
Not Hispanic or Latino
3 Participants3 Participants6 Participants
Race/Ethnicity, Customized
Other
1 Participants0 Participants1 Participants
Race/Ethnicity, Customized
White
2 Participants3 Participants5 Participants
Sex: Female, Male
Female
0 Participants0 Participants0 Participants
Sex: Female, Male
Male
3 Participants3 Participants6 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 30 / 3
other
Total, other adverse events
1 / 33 / 3
serious
Total, serious adverse events
0 / 31 / 3

Outcome results

Primary

Bladder Function Testing

Change in measurements of bladder function (end fill detrusor value) utilizing a urodynamic test consisting of a filling phase and a voiding phase cystometrogram along with perineal patch muscle electromyography.

Time frame: Beginning of study, prior to initiating intervention; End of 4 weeks of intervention.

ArmMeasureGroupValue (MEAN)Dispersion
Percutaneous Epidural StimulationBladder Function TestingPre-intervention21 cm H2OStandard Deviation 15.769168
Percutaneous Epidural StimulationBladder Function TestingPost-intervention54.666667 cm H2OStandard Deviation 32.148959
Transcutaneous Epidural StimulationBladder Function TestingPre-intervention10.5 cm H2OStandard Deviation 5.5
Transcutaneous Epidural StimulationBladder Function TestingPost-intervention15 cm H2OStandard Deviation 15
Primary

Electromyography

Change in voltage measurements in major muscle groups below the level of injury. Specifically, change in soleus root mean square voltage during standing with and without stimulation.

Time frame: Through study completion; an average of 5 months.

ArmMeasureValue (MEAN)Dispersion
Percutaneous Epidural StimulationElectromyography0.00017507 voltsStandard Deviation 0.04279603
Transcutaneous Epidural StimulationElectromyography0.00006740 voltsStandard Deviation 0.0591704
Primary

Female Patient-reported Sexual Function

Measurement of change in sexual function using the Female Sexual Function Index (FSFI). Answers to qualitative questions are rated from 0 to 5, with a higher number indicating better sexual function, and totaled for a score which categorizes severity of sexual dysfunction.

Time frame: Assessed at Baseline, 4 Weeks, 8 Weeks, and 20 Weeks; change from Baseline at week 20 reported.

Population: No female participants were enrolled.

Primary

Foot Pressure

Change in measurements of foot pressure in kilograms through shoe-insole pressure sensors.

Time frame: Beginning of intervention to end of intervention, an average of 17 days.

Population: Increase in the difference in total loading force when standing, between beginning and end of intervention (an average of 17 days), with and without stimulation

ArmMeasureGroupValue (MEAN)Dispersion
Percutaneous Epidural StimulationFoot PressureEnd of intervention40 percentage of loading force increaseStandard Deviation 34
Percutaneous Epidural StimulationFoot PressureBeginning of intervention6 percentage of loading force increaseStandard Deviation 9
Transcutaneous Epidural StimulationFoot PressureBeginning of intervention0 percentage of loading force increaseStandard Deviation 0
Transcutaneous Epidural StimulationFoot PressureEnd of intervention0 percentage of loading force increaseStandard Deviation 0
Primary

Injury Severity: International Standards for Neurological Classification of Spinal Cord Injury

Change sensory and motor function impairment using the American Spinal Injury Association Impairment Scale. Individuals are classified from A (complete SCI) to E (normal function). 28 dermatomes and 10 key muscles are assessed bilaterally. Summed results produce overall sensory and motor scores and combine with evaluation of anal sensory and motor function in determination of AIS classification. Sensory scores are rated 0 (sensation absent) to 2 (normal), bilaterally for each of 28 dermatomes. Muscle function is rated 0 (total paralysis) to 5 (active movement, full range of motion against significant resistance) for each myotome. Upper Extremity Motor Subscores and Lower Extremity Motor Subscores are scored from 0 to 50; the ASIA Motor Score is scored from 0 to 100. The presence of deep anal pressure and voluntary anal contraction are assessed as a yes/no; absence of these, in addition to sensory scores of 0 at S4-5 indicate a Complete injury (otherwise, the injury is Incomplete).

Time frame: Assessed at Baseline, 4 Weeks, 8 Weeks, and 20 Weeks; change from Baseline at week 20 reported.

ArmMeasureGroupValue (NUMBER)
Percutaneous Epidural StimulationInjury Severity: International Standards for Neurological Classification of Spinal Cord InjuryChange between Complete (C) and Incomplete (I) designations0 Participants
Percutaneous Epidural StimulationInjury Severity: International Standards for Neurological Classification of Spinal Cord InjuryChange in ASIA Impairment Scale (AIS) rating0 Participants
Percutaneous Epidural StimulationInjury Severity: International Standards for Neurological Classification of Spinal Cord InjuryChange in sensation of Deep Anal Pressure (DAP)0 Participants
Percutaneous Epidural StimulationInjury Severity: International Standards for Neurological Classification of Spinal Cord InjuryChange in Voluntary Anal Contraction (VAC)0 Participants
Transcutaneous Epidural StimulationInjury Severity: International Standards for Neurological Classification of Spinal Cord InjuryChange in Voluntary Anal Contraction (VAC)0 Participants
Transcutaneous Epidural StimulationInjury Severity: International Standards for Neurological Classification of Spinal Cord InjuryChange between Complete (C) and Incomplete (I) designations0 Participants
Transcutaneous Epidural StimulationInjury Severity: International Standards for Neurological Classification of Spinal Cord InjuryChange in sensation of Deep Anal Pressure (DAP)0 Participants
Transcutaneous Epidural StimulationInjury Severity: International Standards for Neurological Classification of Spinal Cord InjuryChange in ASIA Impairment Scale (AIS) rating0 Participants
Primary

Male Patient-reported Sexual Function (1)

Measurement of change in erectile dysfunction using the Sexual Health Inventory for Men (SHIM). Answers to qualitative questions are rated from 0 to 5, with a higher number indicating better erectile function, and totaled for a score which categorizes severity of erectile dysfunction. Total score can range from 1 to 25, with a lower number indicating more severe erectile dysfunction.

Time frame: Assessed at Baseline, 4 Weeks, 8 Weeks, and 20 Weeks; change from Baseline at week 20 reported.

ArmMeasureValue (MEAN)
Percutaneous Epidural StimulationMale Patient-reported Sexual Function (1)-6.3 Score on a scale
Transcutaneous Epidural StimulationMale Patient-reported Sexual Function (1)0 Score on a scale
Primary

Male Patient-reported Sexual Function (2)

Measurement of change in erectile dysfunction using the International Index for Erectile Function (IIEF). Answers to qualitative questions are rated from 0 to 5, with a higher number indicating better erectile function, and totaled for a score which categorizes severity of erectile dysfunction. Total scores range from 5 to 25, with a lower score indicating more severe erectile dysfunction.

Time frame: Assessed at Baseline, 4 Weeks, 8 Weeks, and 20 Weeks; change from Baseline at week 20 reported.

ArmMeasureValue (MEAN)
Percutaneous Epidural StimulationMale Patient-reported Sexual Function (2)-23.3 Score on a scale
Transcutaneous Epidural StimulationMale Patient-reported Sexual Function (2)-1.5 Score on a scale
Primary

Neurostimulation User Experience

Rating of the subject's perception of individual aspects of spinal stimulation using the User Experience Questionnaire (UEQ), a survey including 26 descriptive terms and their antonyms. A scoring scale ranging from 1 to 7 determines how closely the subject feels the term or its antonym applies to the intervention, with lower numbers indicating agreement with the term, and higher numbers indicating agreement with the antonym. The terms and antonyms describe a positive and negative perception of each item. Subscales grouping terms into like categories average scores into a 7 point range from -3 to +3, with negative averages associated with negative perceptions, and positive averages associated with positive perceptions.

Time frame: End of intervention, an average of 4 weeks

ArmMeasureGroupValue (MEAN)Dispersion
Percutaneous Epidural StimulationNeurostimulation User ExperienceAttractiveness3 Score on a scaleStandard Deviation 0
Percutaneous Epidural StimulationNeurostimulation User ExperiencePerspicuity1.5 Score on a scaleStandard Deviation 0.707
Percutaneous Epidural StimulationNeurostimulation User ExperienceEfficiency2.583 Score on a scaleStandard Deviation 0.382
Percutaneous Epidural StimulationNeurostimulation User ExperienceDependability2.083 Score on a scaleStandard Deviation 0.52
Percutaneous Epidural StimulationNeurostimulation User ExperienceStimulation2.917 Score on a scaleStandard Deviation 0.144
Percutaneous Epidural StimulationNeurostimulation User ExperienceNovelty2.583 Score on a scaleStandard Deviation 0.382
Transcutaneous Epidural StimulationNeurostimulation User ExperienceStimulation2 Score on a scaleStandard Deviation 0.354
Transcutaneous Epidural StimulationNeurostimulation User ExperienceAttractiveness2.5 Score on a scaleStandard Deviation 0
Transcutaneous Epidural StimulationNeurostimulation User ExperienceDependability1.75 Score on a scaleStandard Deviation 0.354
Transcutaneous Epidural StimulationNeurostimulation User ExperiencePerspicuity1.917 Score on a scaleStandard Deviation 0.382
Transcutaneous Epidural StimulationNeurostimulation User ExperienceNovelty1.75 Score on a scaleStandard Deviation 1.414
Transcutaneous Epidural StimulationNeurostimulation User ExperienceEfficiency2 Score on a scaleStandard Deviation 0.354
Primary

Neurostimulator Lead Location and Migration [Epidural Group Only]

Evaluation of current array location via CT.

Time frame: Pre-intervention and 4 weeks post-intervention

Population: Analysis applies only to percutaneous group participants.

ArmMeasureValue (MEDIAN)
Percutaneous Epidural StimulationNeurostimulator Lead Location and Migration [Epidural Group Only]-5.35862 millimeters
Primary

Overground Ambulation [as Appropriate to the Subject]

Measurement of changes in overground mobility as measured by the Modified 6 Minute Walk Test. Trainers will assess the distance in meters which the subject can cover in 6 minutes, with a greater distance characterizing better overground mobility.

Time frame: Baseline, 4 Weeks, 8 Weeks, and 20 Weeks

Population: No Transcutaneous Epidural Stimulation arm participants were ambulatory.

ArmMeasureGroupValue (NUMBER)
Percutaneous Epidural StimulationOverground Ambulation [as Appropriate to the Subject]Pre-intervention to post-intervention9.2 meters
Percutaneous Epidural StimulationOverground Ambulation [as Appropriate to the Subject]Pre-intervention to 8 weeks post intervention16.5 meters
Percutaneous Epidural StimulationOverground Ambulation [as Appropriate to the Subject]Pre-intervention to 20 weeks post intervention16.5 meters
Primary

Patient-reported Bladder Function

Measurement of change in bladder function using the Neurogenic Bladder Symptom Score. Answers to qualitative questions are rated from 0 to 5, with a higher number indicating more problematic symptoms, and totaled for a score which categorizes severity of neurogenic bladder symptoms. The total score can range from 0 (no symptoms at all) to 74 (maximum symptoms).

Time frame: Assessed at Baseline, 4 Weeks, 8 Weeks, and 20 Weeks; change from Baseline at week 20 reported.

ArmMeasureValue (MEAN)
Percutaneous Epidural StimulationPatient-reported Bladder Function-11.3 Score on a scale
Transcutaneous Epidural StimulationPatient-reported Bladder Function-4.5 Score on a scale
Primary

Patient-reported Bowel Function

Measurement of change in bowel function using the Neurogenic Bowel Dysfunction Score. Answers to qualitative questions are rated from 0 to 5, with a higher number indicating more problematic symptoms, and totaled for a score which categorizes severity of neurogenic bowel symptoms. The total score ranges between 0 and 44 points. A higher total score indicates more severe bowel symptoms.

Time frame: Assessed at Baseline, 4 Weeks, 8 Weeks, and 20 Weeks; change from Baseline at week 20 reported.

ArmMeasureValue (MEAN)
Percutaneous Epidural StimulationPatient-reported Bowel Function-4 Score on a scale
Transcutaneous Epidural StimulationPatient-reported Bowel Function-3.5 Score on a scale
Primary

Somatosensory Evoked Potentials

Measurements of change in voltage in the conduction of electricity through the peripheral nerves, cervical and lumbosacral spinal cord, deep brain structures, and sensory cortex, using surface electrodes.

Time frame: Assessed at Baseline, 4 Weeks, 8 Weeks, and 20 Weeks; change from Baseline at week 20 reported.

Population: Change in amplitude of lumbar SSEP during tibial stimulation

ArmMeasureGroupValue (MEAN)Dispersion
Percutaneous Epidural StimulationSomatosensory Evoked PotentialsLeft sided measurements0.67 microvoltsStandard Deviation 0.6
Percutaneous Epidural StimulationSomatosensory Evoked PotentialsRight sided measurements0.33 microvoltsStandard Deviation 0.12
Transcutaneous Epidural StimulationSomatosensory Evoked PotentialsLeft sided measurements0.8 microvoltsStandard Deviation 0.99
Transcutaneous Epidural StimulationSomatosensory Evoked PotentialsRight sided measurements0.35 microvoltsStandard Deviation 0.07
Primary

Spasticity

Change in measurements of spasticity using the Spinal Cord Injury Spasticity Evaluation Tool (SCI-SET). Answers to qualitative questions are rated from -3 to +3, with a higher positive number indicating more helpful symptoms, and a lower negative number indicating more problematic symptoms. Questions may also be answered as not applicable (N/A), which do not generate a score. Scores are totaled for a score which categorizes the overall positive or negative impact of a subject's spasticity symptoms. Total score can range from -105 (negative impact) to +105 (positive impact), and the score is averaged by total positive or negative score divided by the number of applicable answers.

Time frame: Assessed at Baseline, 4 Weeks, 8 Weeks, and 20 Weeks; change from Baseline at week 20 reported.

ArmMeasureValue (MEDIAN)
Percutaneous Epidural StimulationSpasticity0.057 Score on a scale
Transcutaneous Epidural StimulationSpasticity0.088 Score on a scale
Primary

Transcranial Magnetic Stimulation Motor Evoked Potentials

Measurement of the threshold percentage change in voltage between pre-intervention and post-intervention in the first trapezius or deltoid muscle activated.

Time frame: Assessed at Baseline, 4 Weeks, 8 Weeks, and 20 Weeks; change from Baseline at week 20 reported.

ArmMeasureValue (MEAN)Dispersion
Percutaneous Epidural StimulationTranscranial Magnetic Stimulation Motor Evoked Potentials3.33 percent changeStandard Deviation 5.77
Transcutaneous Epidural StimulationTranscranial Magnetic Stimulation Motor Evoked Potentials5 percent changeStandard Deviation 7.07
Primary

Trunk Stability

Changes in trunk stability based on stable forward reach measured in centimeters, with a greater distance of forward reach characterizing greater trunk stability. Specifically, change in forward reach at the end of the study when comparing stimulation assisted reach and non-stimulation assisted reach.

Time frame: Beginning of intervention to end of intervention, an average of 17 days, 8 weeks post beginning of intervention, 20 weeks post beginning of intervention; change from beginning of intervention at week 20 reported.

ArmMeasureGroupValue (MEAN)Dispersion
Percutaneous Epidural StimulationTrunk StabilityNon-stimulation assisted reach14.933333 centimetersStandard Deviation 9.3972809
Percutaneous Epidural StimulationTrunk StabilityStimulation assisted reach34.933333 centimetersStandard Deviation 14.115319
Transcutaneous Epidural StimulationTrunk StabilityNon-stimulation assisted reach3 centimetersStandard Deviation 3
Transcutaneous Epidural StimulationTrunk StabilityStimulation assisted reach21.5 centimetersStandard Deviation 11

Source: ClinicalTrials.gov · Data processed: Aug 22, 2026